Navigation Links
Prostate cancer risk variant found to be in a functional DNA sequence linked with disease

July 13, 2010 Recent genetic association studies have uncovered a number of DNA variants associated with prostate cancer. However, some of these risk variants lie outside of genes, posing a challenge to researchers working to understand the biology of cancer. In a report published online today in Genome Research (, researchers have characterized a functional DNA element associated with prostate cancer, lending new insight into the molecular mechanisms of the disease.

Genome wide association studies (GWAS) have uncovered numerous genetic variants that confer increased risk to disease, and interestingly, many reside in genomic regions that lack genes. Although the DNA may not code for a gene, it could still play a functional role. "This raises the question of what non-coding DNA within these gene deserts actually has biological function, and how differences within a functional non-coding element could underlie disease risk," said Marcelo Nobrega of the University of Chicago, senior author of the study.

Recent GWAS have implicated a specific region of chromosome 8, known as 8q24, for harboring non-coding risk variants for several different cancers, including particularly strong associations with prostate cancer. Variants in this region could lie within enhancer elements, non-coding DNA sequences that control how, when, and where genes are expressed. An altered enhancer sequence could significantly change the normal expression of critical genes, increasing risk for disease.

To test this hypothesis, the group designed an experiment to investigate the enhancer activity of human 8q24 DNA fragments and whether risk alleles of the enhancer modify that activity. The group engineered DNA segments that included the human sequences and a "reporter" gene that would indicate whether any enhancers are present in the human DNA.

They then created transgenic mice that harbored the engineered DNA sequences in every cell of the animal. If a human enhancer interacts with the reporter gene in any tissue, the cells turn blue when treated with a stain.

"By looking at the transgenic mice we noticed that their prostate and mammary glands were blue," Nobrega noted, "indicating the presence of regulatory sequences within the piece of human DNA that we were testing." They then focused on the prostate, identifying the specific enhancer driving the observed expression pattern.

The group could then engineer a version of the enhancer that contained a risk variant associated with prostate cancer and test this in mice. The prostate enhancer harboring the risk allele in the sequence drove expression of the reporter gene significantly higher in the mouse prostate relative to the normal version of the enhancer.

"The fact that a single nucleotide difference so markedly altered the enhancer's activity within the context of a living organism clearly demonstrates the potential impact that variation within non-coding gene regulatory elements could have on disease state," Nobrega noted.

Previous research has indicated that this enhancer modifies activity of a nearby gene called MYC, a proto-oncogene that exhibits altered expression in prostate cancers. However, those studies found no correlation between the risk allele enhancer and MYC expression in normal or cancerous prostate tissues, suggesting altered MYC expression may not be the biological factor conferring risk to disease in these cases.

The authors further explained that the risk variant enhancer activity was observed in the prostate throughout organogenesis and development, suggesting that the cancer risk variant might assert its influence very early, long before a tumor forms. "This strengthens the notion of a pathogenic process that could initiate much earlier in life than the appearance of clinical alterations, one in which this prostate enhancer could potentially play a part," said Nora Wasserman, primary author of the study.


Contact: Peggy Calicchia
Cold Spring Harbor Laboratory

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
3. Orange Coast Urology Offers Advanced In-Office Patient EVOLVE(R) Laser Prostate Treatment
4. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
5. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
8. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans
9. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
10. Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varians RapidArc(TM) Radiotherapy
11. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
Post Your Comments:
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
Breaking Biology News(10 mins):